Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Dec;68(12):e29333.
doi: 10.1002/pbc.29333. Epub 2021 Sep 8.

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Anderson B Collier 3rd  1 , Mark D Krailo  2 , Ha M Dang  2 , Steven G DuBois  3 , Douglas S Hawkins  4 , Mark L Bernstein  5 , Lisa R Bomgaars  6 , Damon R Reed  7 , Richard G Gorlick  8 , Katherine A Janeway  3
Affiliations
Clinical Trial

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Anderson B Collier 3rd et al. Pediatr Blood Cancer. 2021 Dec.

Abstract

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

Keywords: Ewing sarcoma; event-free survival; objective response; outcome; phase 2 trials; relapsed.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement:

Anderson B Collier, Ha M Dang, Mark L Bernstein, and Richard G Gorlick: None declared

Mark D Kraillo: DSMC consulting fee from Merck

Steven G DuBois: Travel reimbursement from Loxo Oncology, Roche, and Salarius; consulting fee from Bayer and Loxo Oncology

Douglas S Hawkins: Travel reimbursement from Lilly, Bristol Myers Squibb, Celgene, Loxo Oncology, & Bayer

Lisa R Bomgaars: Unpaid consultant for Janssen & Boehringer Ingelheim

Damon R Reed: Consulting fee or advisory board from Epizyme, Jannsen, Shire, Loxo Oncology; Travel reimbursement from Salarius

Katherine A Janeway: Consulting fee from Bayer, Ipsen, Honoraria from Foundation Medicine and Takeda

Figures

FIGURE 1
FIGURE 1
Event free survival of the entire cohort of patients with relapsed or progressive Ewing sarcoma enrolled on the seven phase II trials. (n=128)
See this image and copyright information in PMC

References

    1. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H. Ewing’s sarcoma family of tumors: Current management. Oncologist 2006:11:503–519. - PubMed
    1. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jurgens H. Primary disseminated multifocal ewing sarcoma: Results of the euro-ewing 99 trial. J Clin Oncol 2010:28:3284–3291. - PubMed
    1. Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, Gebhardt M, Grier HE. Prognostic factors for patients with ewing sarcoma (ews) at first recurrence following multi-modality therapy: A report from the children’s oncology group. Pediatr Blood Cancer 2008:51:334–338. - PMC - PubMed
    1. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized ewing sarcoma: A report from the children’s oncology group. J Clin Oncol 2012:30:4148–4154. - PMC - PubMed
    1. Beaty O 3rd, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC. A phase ii trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A children’s oncology group study. Pediatr Blood Cancer 2010:55:440–445. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts